Routy, Bertrand http://orcid.org/0000-0003-1955-9149
Lenehan, John G.
Miller, Wilson H. Jr
Jamal, Rahima
Messaoudene, Meriem
Daisley, Brendan A. http://orcid.org/0000-0001-5999-5792
Hes, Cecilia http://orcid.org/0000-0002-4828-3260
Al, Kait F. http://orcid.org/0000-0002-5905-6581
Martinez-Gili, Laura http://orcid.org/0000-0001-5271-9672
Punčochář, Michal http://orcid.org/0000-0002-1915-9391
Ernst, Scott
Logan, Diane
Belanger, Karl
Esfahani, Khashayar
Richard, Corentin
Ninkov, Marina
Piccinno, Gianmarco
Armanini, Federica
Pinto, Federica http://orcid.org/0000-0002-4539-4811
Krishnamoorthy, Mithunah
Figueredo, Rene
Thebault, Pamela
Takis, Panteleimon http://orcid.org/0000-0002-7224-0412
Magrill, Jamie
Ramsay, LeeAnn
Derosa, Lisa http://orcid.org/0000-0003-0527-2964
Marchesi, Julian R.
Parvathy, Seema Nair
Elkrief, Arielle
Watson, Ian R. http://orcid.org/0000-0002-6025-3080
Lapointe, Rejean
Segata, Nicola
Haeryfar, S.M. Mansour http://orcid.org/0000-0002-1125-8176
Mullish, Benjamin H. http://orcid.org/0000-0001-6300-3100
Silverman, Michael S.
Burton, Jeremy P. http://orcid.org/0000-0002-3591-6436
Maleki Vareki, Saman http://orcid.org/0000-0002-9615-7779
Funding for this research was provided by:
Lotte and John Hecht Memorial Foundation
Canadian Institute of Health Research
Canadian Cancer Society Impact Grant
Article History
Received: 9 February 2023
Accepted: 8 June 2023
First Online: 6 July 2023
Change Date: 3 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-023-02650-8
Competing interests
: B.R. reports grants from Kaleido, Vedanta, Surface and Da Volterra outside the submitted work, as well as consulting fees from BMS, AstraZeneca, Merck and Da Volterra. He is also the co-founder of Science Curebiota. B.H.M. has received consultancy fees from Finch Therapeutics Group and Ferring Pharmaceuticals, outside of the submitted work. R.J. reports grants from BMS, Merck and Iovance Biotherapeutics as well as consulting fees from BMS and Merck. M.K. is an employee at Pfizer. L.D. had consulting and advisory roles for BMS, Sanofi and EverImmune and was supported by the Philantropia Fondation Gustave Roussy. J.R.M. has received consultancies from Enterobiotix and Cultech outside of the submitted work. S.M.V. is a director of the board of IMV. The remaining authors declare no competing interests.